Molecular diagnostics company Diacarta Ltd. raised $45 million in its most recent series B funding, and will apply the capital to expand its liquid biopsy cancer detection platform. The cash flow will be used toward Diacarta's XNA technology platform to detect cancer at an early stage, and to expand globally.